HOOKIPA PHARMA INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 14 rows in 2023. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2023-06-09: Reporting owner Peters Malte; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2023-06-09: Reporting owner Reilly Timothy P.; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2023-06-09: Reporting owner O'Neill Julie; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2023-06-09: Reporting owner van de Winkel Jan; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2023-06-09 | Peters Malte Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +52,000 52,000 owned after | $1.01 exercise price | 2023-06-09 | |
| 2023-06-09 | Reilly Timothy P. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +26,000 26,000 owned after | $1.01 exercise price | 2023-06-09 | |
| 2023-06-09 | O'Neill Julie Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +26,000 26,000 owned after | $1.01 exercise price | 2023-06-09 | |
| 2023-06-09 | van de Winkel Jan Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +52,000 52,000 owned after | $1.01 exercise price | 2023-06-09 | |
| 2023-06-09 | Kaufman David Ross Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +26,000 26,000 owned after | $1.01 exercise price | 2023-06-09 | |
| 2023-06-09 | Coelho Mary Theresa Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +52,000 52,000 owned after | $1.01 exercise price | 2023-06-09 | |
| 2023-04-18 holding as of filing | Schlienger Katia Officer (Chief Medical Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $12.00 exercise price | 2023-04-18 | ||
| 2023-04-18 holding as of filing | Schlienger Katia Officer (Chief Medical Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.66 exercise price | 2023-04-18 | ||
| 2023-04-14 | Orlinger Klaus Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +194,200 194,200 owned after | $1.00 exercise price | 2023-04-18 | |
| 2023-04-14 | Necina Roman Officer (Chief Development Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +112,100 112,100 owned after | $1.00 exercise price | 2023-04-18 | |
| 2023-04-14 | Schlienger Katia Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +184,000 184,000 owned after | $1.00 exercise price | 2023-04-18 | |
| 2023-04-14 | Baker Christine D. Officer (Chief Operating Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +275,800 275,800 owned after | $1.00 exercise price | 2023-04-18 | |
| 2023-04-14 | Kandera Reinhard Director, Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +214,800 214,800 owned after | $1.00 exercise price | 2023-04-18 | |
| 2023-04-14 | Aldag Jorn Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +513,600 513,600 owned after | $1.00 exercise price | 2023-04-18 |